期刊文献+

CAG方案联合中药扶正解毒治疗急性髓系白血病的临床观察

Clinical Observation on CAG Regimen Combined with TCM in Treatment of Acute Myeloid Leukemia
下载PDF
导出
摘要 目的:观察CAG方案联合中药扶正解毒治疗急性髓系白血病的疗效和安全性。方法:19例急性髓系白血病患者应用CAG方案(阿糖胞苷10 mg/m2,q12 h,皮下注射,第1~14天,阿柔吡星20mg,第1,3,5,7天,粒细胞集落刺激因子200μg/m2,1次/d)联合中药扶正解毒治疗。观察患者疗效及不良反应。结果:19例AML患者,临床有效14例(73.4%),其中完全缓解11例(57.9%),部分缓解3例(15.8%),无效5例(26.3%)。结论:CAG方案联合中药扶正解毒治疗急性髓系白血病疗效可靠,不良反应少,安全性高,化疗相关死亡率低。 Objective:To investigate the curative effect and safety of CAG regimen combined with traditional Chinese medicine treatment for acute myeloid leukemia (AML) patients. Methods : 19 cases of AML patients were treated with CAG regimen( Ara - C 10 mg/m2 ,once every 12 h by subcutaneous injection;1 - 14 d, aelarubicin 20 mg;1 d,3 d,5 d,7 d,G - CSF 200 μg/m2, once a day) combined with traditional chinese medicine. Results :Effective rate was 73.4%. CR was 57.9%. PR was 15.8% and NR was 26.3%. Conclusion:CAG regimen combined with traditional Chinese medicine is an effective treatment for the AML patients with high safety and low treatment - related mortality.
出处 《辽宁中医杂志》 CAS 2014年第8期1651-1652,共2页 Liaoning Journal of Traditional Chinese Medicine
关键词 CAG方案 中药 急性髓系白血病 CAG regimen traditional Chinese medicine acute myeloid leukemia
  • 相关文献

参考文献5

  • 1Saito K, Furusawa S, Yamada K, et al. Comparison of low - dose cyto- sine arabinoside and aclarubicin in combination with granulocyte colo- ny - stimulating factor to intermediate - dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed a- cute myeloid leukemia[J]. Rinsho Ketsueki, 1995,36 (3) : 165 - 74.
  • 2Yamada K, Furusawa S, Saito K, et al. Concurrent use of granuloeyte colony- stimulating factor with low - dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia : a pilot study [ J ]. Leukemia, 1995,9 ( 1 ) : 10 - 4.
  • 3Graf M, Hecht K, Reif S,et al. Expression and prognostic value of he- mopoietic cytokine receptors in acute myeloid leukemia (AML) :im- plications for future therapeutical strategies [ J ]. Eur J Haematol, 2004,72(2) :89 - 106.
  • 4廖斌,葛仁英,陈霞,皇甫真萍,齐彦,宋永平,魏旭东.中药复方君子汤联合环孢霉素A逆转白血病细胞株K562/VCR耐药性的实验研究[J].中国实验血液学杂志,2007,15(4):752-755. 被引量:24
  • 5华自森,王建伟,宋姝丹,王亚平.当归多糖对K562白血病细胞JAK2、STAT3表达和活化的影响[J].解剖学杂志,2009,32(1):8-11. 被引量:18

二级参考文献16

  • 1胡晶,吴宏.当归多糖对小鼠外周血造血干细胞动员作用的研究[J].中草药,2006,37(12):1835-1838. 被引量:47
  • 2Niu G, Wright K L, Ma Y, et al. Role of STAT3 in regulating p53 expression and function[J]. Mol Cell Biol, 2005, 25:7432-7440.
  • 3Gritsko T, Williams A, Turkson J, et al. Persistent activation of STAT3 signaling induces survivin gene expression and confers re sistance to apoptosis in human breast cancer cells [J]. Clin Cancer Res, 2006, 12(1):11-19.
  • 4Ning Z Q, Li J, Arceci R J. Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells[J]. Blood, 2001,97 ( 11 ): 3559-3567.
  • 5Buettner R, More L B, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention[J]. Clin Cancer Res, 2002,8(4) :945-954.
  • 6Nam S, Buettner R, Turkson J. Indirubin derivatives inhibit STAT3 signaling and induce apoptosis in human cancer cells[J]. Proe Natl Acad Sci U S A, 2005,102(17):5998-6003.
  • 7Yu H, Jove R. The STATs of cancer- new molecular targets come of age [J]. Nat Rev Cancer, 2004,4:97-105.
  • 8Nielsen M, Kaestel C G, Eriksen K W, et al. Inhibition of constitutively activated STAT3 correlates with altered Bcl-2/Bax ex pression of Bcl-xL [J]. Leukemia, 1999,13(5):735-738.
  • 9Saharinen P, Ekman N, Sarvas K, et al. The Bmx tyrosine kinase induces activation of the STAT signaling pathway which is specifically inhibited by protein kinase C delta[J]. Blood, 1997, 90(11) :4341-4353.
  • 10Chong C D, Liao J, Lio H, et al. Specific inhibition of STAT3 signal transduction by PLAS3 [J].Science, 1997, 278 (5344):1803-1805.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部